Aripiprazole

Antipsychotics differed in their efficacy in preventing relapse hospitalization and treatment failure among patients with schizophrenia spectrum disorder, according to research published in JAMA Network Open.

Long-acting injectable formulations of paliperidone, aripiprazole and olanzapine had the highest effect sizes and certainty of evidence for relapse prevention and acceptability, researchers noted in American Journal of Psychiatry.

Aripiprazole lauroxil offered safe and clinically significant symptom improvement for patients with schizophrenia, according to study results published in Journal of Clinical Psychiatry.

Individuals with depression who experienced loss of interest and reduced activity appeared to benefit more from aripiprazole augmentation than escitalopram monotherapy, according to findings published in Journal of Clinical Psychiatry.

Aristada Initio and Invega Sustenna appeared well tolerated and effective for initiating in-hospital schizophrenia treatment and continuing outpatient treatment, according to a study published in Journal of Clinical Psychiatry.